Skip to Main Content

++

INTRODUCTION

++

triazolam (trye-az-oh-lam)

Image not available.Apo-Triazo, Image not available.Gen-Triazolam, Halcion, Image not available.Novo-Triolam, Image not available.Nu-Triazo

Classification

Therapeutic: sedative/hypnotics

Pharmacologic: benzodiazepines

Schedule IV

++
Indications
++

Short-term management of insomnia.

++
Action
++

Acts at many levels in the CNS, producing generalized depression. Effects may be mediated by gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. Therapeutic Effects: Relief of insomnia.

++
Adverse Reactions/Side Effects
++

CNS: abnormal thinking, behavior changes, dizziness, excessive sedation, hangover, headache, anterograde amnesia, confusion, hallucinations, sleep driving, lethargy, mental depression, paradoxical excitation. EENT: blurred vision. GI: constipation, diarrhea, nausea, vomiting. Derm: rashes. Misc: physical dependence, psychologic dependence, tolerance.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor daytime drowsiness, anxiety, short-term memory deficits, and “hangover” symptoms (headache, blurred vision, nausea, irritability, lethargy, dysphoria). Repeated or excessive symptoms may require change in dose or medication.

  • Watch for other behavioral or personality changes such as confusion, nervousness, excitation, decreased concentration, hallucinations, or expression of abnormal thoughts. Notify physician if these changes become problematic.

  • Assess dizziness that might affect gait, balance, and other functional activities (See Appendix C). Report balance problems and functional limitations to the physician, and caution the patient and family/caregivers to guard against falls and trauma.

++
Interventions
++

  • Guard against falls and trauma (hip fractures, head injury, and so forth). Implement fall-prevention strategies, especially in older adults or if drowsiness and dizziness carry over into the daytime (See Appendix E).

  • Help patient explore nonpharmacologic methods to improve sleep, such as relaxation techniques, regular exercise, avoid caffeine, and so forth.

++
Patient/Client-Related Instruction
++

  • Instruct patients on prolonged treatment not to discontinue medication without consulting their physician. Long-term use can cause tolerance and physical/psychologic dependence, and increased sleep problems (rebound insomnia) can occur when the drug is suddenly discontinued.

  • Advise patient to avoid alcohol and other CNS depressants because of the increased risk of sedation and adverse effects.

  • Caution patient and family/caregivers to guard against complex motor behaviors that can occur while asleep, including driving a car.

  • Instruct patient to report severe or prolonged skin rash or GI problems (nausea, vomiting, diarrhea, constipation).

++
Pharmacokinetics
++

Absorption: Well absorbed following oral administration.

++

Distribution: Widely distributed, crosses blood-brain barrier. Probably crosses the placenta and enters breast milk.

++

Protein Binding: 89%.

++

Metabolism and Excretion: Metabolized by the liver.

++

Half-life: 1.6–5.4 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE (sedation)

ROUTE ONSET PEAK DURATION
PO 15–30 min 6–8 hr unknown

++
Contraindications/Precautions
++

Contraindicated in: Hypersensitivity; Cross-sensitivity with other benzodiazepines may occur; Preexisting CNS depression; Uncontrolled severe pain; OB/Pedi: Pregnancy, lactation, or children.

++

Use ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.